Results from an early phase clinical trial presented this week at the World Conference on Lung Cancer Meeting in Barcelona, Spain, and published in the Nature Medicine journal show that patients with mesothelioma - a rare cancer of the lining of the lung that may be caused by exposure to asbestos - who received a combination of two immunotherapy drugs, nivolumab and ipilimumab, before surgery had successful surgeries and encouraging early outcomes.  

A new study from the University of Missouri is helping veterinarians and pet owners better understand how to treat thyroid cancer in dogs by studying how to improve treatment with a type of therapy called radioactive iodine. It lays the important groundwork for delivering more tailored and effective treatment options.

New research presented identifies interferon-induced transmembrane protein 3 (IFITM3) as a critical regulator of immunotherapy sensitivity in small cell lung cancer (SCLC), offering a promising new avenue for overcoming resistance to PD-1/PD-L1 checkpoint blockade.

The research was presented at the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer (WCLC).

A new analysis from the PALOMA-2 study presented today shows that subcutaneous administration of amivantamab every four weeks (Q4W), in combination with daily oral lazertinib, yields a high objective response rate in patients with previously untreated EGFR-mutated advanced non-small cell lung cancer (NSCLC).

The results were presented at the International Association for the Study of Lung Cancer at the 2025 World Conference on Lung Cancer (WCLC).

A new technique has measured boron in individual cancer cells for the first time, enabling researchers to better understand how drugs act to kill tumours in some cancers, in a new article published in the Journal of Analytical Atomic Spectrometry,